ETON Stock Analysis: Buy, Sell, or Hold?
ETON - Eton Pharmaceutcials, Inc. Common Stock
$29.96
-0.86 (-2.79%)
▼
5d:
-3.42%
30d:
+11.09%
90d:
+78.44%
BUY
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Smart Money Accumulation
ETON is down 3.4% this week, but smart money is accumulating calls. Top strike: $35 2026-06-18 with 257 OI. Call ratio: 100% View Scanner →
Strength: 6.7/10
Get Alerted When ETON Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called ETON this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 1.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ETON shows positive signals but monitor for confirmation. Market pricing in 1.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$60.73
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$37.71
20.5% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 16.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ETON is currently trading at $29.96, which is considered extended relative to its 30-day fair value range of $23.97 to $29.39. The stock's valuation (Forward PE: 15.8) is in line with its historical norms (16.5). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $24.61, while resistance sits at $32.31.
Market Sentiment: ETON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.00 (+36.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ETON is in a strong uptrend. Immediate support is located at $24.61, while resistance sits at $32.31.
Market Sentiment: ETON has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $41.00 (+36.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$23.97 -
$29.39
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
69.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 36.8% below Wall St target ($41.00)
Trading Range Analysis
30-Day Trading Range
$23.97 -
$29.39
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$3.53
(11.8%)
Support & Resistance Levels
Support Level
$24.62
Resistance Level
$32.31
Current Trend
Strong Uptrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
15.85
Wall Street Target
$41.00
(+36.8%)
Revenue Growth (YoY)
82.7%
Earnings Growth (YoY)
-12.6%
Profit Margin
-5.8%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
15.9 vs 16.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$29.54
(-1%)
2-Year Target
$29.13
(-3%)
3-Year Target
$28.72
(-4%)
3-Yr Target (if PE normalizes)
(PE: 16→17)
$29.89
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.0, Growth: 83.5%)
$140.59
(+369%)
Base:
(SPY PE: 15.9, Growth: 83.5%)
$101.11
(+238%)
Bear:
(PE: 13.5, Growth: 83.5%)
$85.95
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 15.9 to 16.5
Stabilization Target:
$31.18
(+4.1%)
PE Expansion Potential:
+4.1%
Share & Embed Analysis
Last updated: May 14, 2026 7:22 PM ET
Data refreshes hourly during market hours. Next update: 8:22 PM
Data refreshes hourly during market hours. Next update: 8:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ETON showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 56 HOLD |
